Plant-derived vaccines against diarrhoeal diseases

Expert Opinion on Biological Therapy

Volumn 4, Issue 5, 2004, Pages 719-728

  Tacket, Carol O ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Cholera; Diarrhoea; E. coli; Norovirus; Transgenic plants; Vaccine

Indexed keywords

ANTIGEN; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; PLANT DERIVED VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; CHOLERA; CLINICAL TRIAL; CORN; DIARRHEA; DRUG SAFETY; ESCHERICHIA COLI; GENE; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INTESTINE INFECTION; LT B GENE; NOROVIRUS; POTATO; REVIEW; TRANSGENIC PLANT; VACCINATION; VIRUS INFECTION;

ADMINISTRATION, ORAL; ANIMALS; DIARRHEA; HUMANS; LEGISLATION, DRUG; PLANTS; PLANTS, GENETICALLY MODIFIED; VACCINES;

ANIMALIA; ESCHERICHIA COLI; NOROVIRUS; SOLANUM TUBEROSUM; ZEA MAYS;

EID: 2442689039     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.5.719     Document Type: Review

References (108)

1. TACKET CO, SZTEIN MB, WASSERMAN SS et al.: Phase II clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in US volunteers. Infect. Immun. (2000) 68:1196-1201.
2. KOTLOFF KL, TAYLOR DN, SZTEIN MB et al.: Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect. Immun. (2002) 70:2016-2021.
3. KOTLOFF KL, NORIEGA F, LOSONSKY GA et al: Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect. Immun. (1996) 64:4542-4548.
4. EDELMAN R: Adjuvants for the future. In: New Generation Vaccines. Levine MM, Woodrow GC, Kaper JB, Cobon GS (Eds), Marcel Dekker, Inc., New York, USA (1997):173-192.
5. GRANGETTE C, MULLER-ALOUF H, GEOFFROY M, GOUDERCOURT D, TURNEER M, MERCENIER A: Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence. Vaccine (2002) 20:3304-3309.
6. SCHEPPLER L, VOGEL M, ZUERCHER AW et al.: Recombinant Lactobacillus johnsonii as a mucosal vaccine delivery vehicle. Vaccine (2002) 20:2913-2920.
7. ZEGERS ND, KLUTER E, VAN DER STAP H et al: Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax. J. Appl Microbiol. (1999) 87:309-314.
8. POUWELS PH, LEER RJ, BOERSMA WJ: The potential of Lactobacillus as a carrier for oral immunization: development and preliminary characterization of vector systems for targeted delivery of antigens. J. Biotechnol. (1996) 44:183-192.
9. DEVICO AL, FOUTS TR, SHATA MT, KAMIN-LEWIS R, LEWIS GK, HONE DM: Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine (2002) 20:1968-1974.
10. ORR N, GALEN JE, LEVINE MM: Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM(197), and its fragments in Salmonella typhi vaccine strain CVD 908-htrA. Infect. Immun. (1999) 67:4290-4294.
11. DIPETRILLO MD, TIBBETTS T, KLEANTHOUS H, KILLEEN KP, HOHMANN EL: Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine (1999) 18:449-459.
12. TACKET CO, KELLY SM, SCHODEL F et al.: Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect. Immun. (1997) 65:3381-3385.
13. TACKET CO, GALEN J, SZTEIN MB et al.: Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin. Immunol. (2000) 97:146-153.
14. NARDELLI-HAEFLIGER D, KRAEHENBUHL JP, CURTISS R III et al: Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect. Immun. (1996) 64:5219-5224.
15. GIDDINGS G: Transgenic plants as protein factories. Curr. Opin. Biotechnol. (2001) 12:450-454.
16. GIDDINGS G, ALLISON G, BROOKS D, CARTER A: Transgenic plants as factories for biopharmaceuticals. Nat. Biotechnol. (2000) 18:1151-1155.
17. LARRICK JW, THOMAS DW: Producing proteins in transgenic plants and animals. Curr. Opin. Biotechnol. (2001) 12:411-418.
18. MA JK, HIATT A, HEIN M et al.: Generation and assembly of secretory antibodies in plants. Science (1995) 268:716-719.
19. MA JK, HIKMAT BY, WYCOFF K et al.: Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat. Med. (1998) 4:601-606.
20. CHARGELEGUE D, VINE ND, VAN DOLLEWEERD CJ, DRAKE PM, MA JK: A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice. Transgenic Res. (2000) 9:187-194.
21. FISCHER R, HOFFMANN K, SCHILLBERG S, EMANS N: Antibody production by molecular farming in plants. J. Biol. Regul. Homeost. Agents (2000) 14:83-92.
22. ZEITLIN L, OLMSTED SS, MOENCH TR et al.: A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat. Biotechnol. (1998) 16:1361-1364.
23. WALMSLEY AM, ALVAREZ ML, JIN Y et al.: Expression of the B subunit of Escherichia coli heat-labile enterotoxin as a fusion protein in transgenic tomato. Plant Cell Rep. (2003) 21:1020-1026.
24. SMITH G, WALMSLEY A, POLKINGHORNE I: Plant-derived immunocontraceptive vaccines. Reprod Fertil. Dev. (1997) 9:85-89.
25. HOOD EE, KUSNADI A, NIKOLOV Z, HOWARD JA: Molecular farming of industrial proteins from transgenic maize. Adv. Exp. Med. Biol. (1999) 464:127-147.
26. KUSNADI AR, EVANGELISTA RL, HOOD EE, HOWARD JA, NIKOLOV ZL: Processing of transgenic corn seed and its effect on the recovery of recombinant beta-glucuronidase. Biotechnol. Bioeng. (1998) 60:44-52.
27. HOOD EE, WITCHER DR, MADDOCK S et al.: Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification. Mol. Breeding (1997) 3:291-306.
28. KUSNADI AR, HOOD EE, WITCHER DR, HOWARD JA, NIKOLOV ZL: Production and purification of two recombinant proteins from transgenic corn. Biotechnol. Prog. (1998) 14:149-155.
29. DANIELL H, STREATFIELD SJ, WYCOFF K: Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci. (2001) 6:219-226.
30. MA SW, ZHAO DL, YIN ZQ et al.: Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nat. Med (1997) 3:793-796.
31. STREATFIELD SJ, LANE JR, BROOKS CA et al.: Corn as a production system for human and animal vaccines. Vaccine (2003) 21:812-815. Description of LT-B expressed in defatted corn germ prepared from transgenic corn.
32. CHIKWAMBA R, CUNNICK J, HATHAWAY D, MCMURRAY J, MASON H, WANG K: A functional antigen in a practical crop: LT-B producing maize protects mice against Escherichia coli heat labile enterotoxin (LT) and cholera toxin (CT). Transgenic Res. (2002) 11:479-493. Description of LT-B expressed in transgenic corn germ meal.
33. SALA F, MANUELA RM, BARBANTE A, BASSO B, WALMSLEY AM, CASTIGLIONE S: Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives. Vaccine (2003) 21:803-808. Review of plant-derived vaccines, including a description of integration of gene into chloroplast.
34. MASON HS, ARNTZEN CJ: Transgenic plants as vaccine production systems. Trends Biotechnol. (1995) 13:388-392.
35. CHRISTOU P, FORD T, KOFRON M: Production of transgenic rice (Oryza sativa L.) plants from agronomically important indica and japonica varieties via electric discharge particle acceleration of exogenous DNA into immature zygotic embryos. Bio/Technology (1999) 9:957-962.
36. ZAMBRYSKI P: Basic processes underlying Agrobacterium-mediated DNA transfer to plant cells. Ann. Rev. Genet. (1988) 22:1-30.
37. NIKOLOV Z, HAMMES D: Production of recombinant proteins from transgenic crops. In: Plants as Factories for Protein Production. Hood E, Howard J (Eds), Kluwer Academic Publishers, Dordrecht, The Netherlands (2002).
38. SAVARINO SJ, HALL ER, BASSILY S et al.: Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr. Infect. Dis. J. (2002) 21:322-330.
39. CLEMENS JD, SACK DA, HARRIS JR et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J. Infect. Dis. (1988) 158:372-377.
40. HAQ TA, MASON HS, CLEMENTS JD, ARNTZEN CJ: Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science (1995) 268:714-716. Early description of construction of transgenic tobacco and potato plants expressing LT-B and their immunogenicity in mice.
41. MASON HS, HAQ TA, CLEMENTS JD, ARNTZEN CJ: Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine (1998) 16:1336-1343. Demonstration of immunogenicity of transgenic plant vaccine expressing LT-B and protection of immunised mice against LT challenge.
42. TACKET CO, MASON HS, LOSONSKY G, CLEMENTS JD, LEVINE MM, ARNTZEN CJ: Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat. Med. (1998) 4:607-609. Phase I human study of safety and immunogenicity of transgenic vaccine consisting of potato-expressed LT-B.
43. STREATFIELD SJ, JILKA JM, HOOD EE et al.: Plant-based vaccines: unique advantages. Vaccine (2001) 19:2742-2748. Corn-derived vaccine expressing LT-B and spike protein of swine transmissible gastroenteritis virus in mice.
44. WOODARD SL, MAYOR JM, BAILEY MR et al.: Maize (Zea mays)-derived bovine trypsin: characterization of the first large-scale, commercial protein product from transgenic plants. Biotechnol. Appl. Biochem. (2003) 38:123-130.
45. STREATFIELD SJ, MAYOR JM, BARKER DK: Development of an edible subunit vaccine in corn against enterotoxigenic strains of Escherichia coli. In Vitro Cell. Dev. Biol. Plant (2002) 38:11-17.
46. LAMPHEAR BJ, STREATFLELD SJ, JILKA JM et al.: Delivery of subunit vaccines in maize seed. J. Control. Release (2002) 85:169-180.
47. TACKET CO, PASETTI MF, EDELMAN R, HOWARD JA, STREATFIELD S: Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine (2004) (In Press). Phase I study of transgenic corn germ meal expressing LT-B.
48. ARAKAWA T, CHONG DK, LANGRIDGE WH: Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat. Biotechnol. (1998) 16:292-297. Potato-derived CT-B vaccine in mice stimulates neutralising anti-CT responses in vitro.
49. ARAKAWA T, YU J, LANGRIDGE WH: Food plant-delivered cholera toxin B subunit for vaccination and immunotolerization. Adv. Exp. Med. Biol. (1999) 464:161-178.
50. ARAKAWA T, CHONG DK, MERRITT JL, LANGRIDGE WH: Expression of cholera toxin B subunit oligomers in transgenic potato plants. Transgenic Res. (1997) 6:403-413.
51. CLEMENS JD, SACK DA, RAO MR et al.: Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area. J. Infect. Dis. (1992) 166:1029-1034.
52. GLASS RI, NOEL J, ANDO T et al.: The epidemiology of enteric caliciviruses from humans: a reassessment using new diagnostics. J. Infect. Dis. (2000) 181(Suppl. 2):S254-S261.
53. GREEN KY, LEW JF, JIANG X, KAPIKIAN AZ, ESTES MK: Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. J. Clin. Microbiol. (1993) 31:2185-2191.
54. DENEEN VC, HUNT JM, PAULE CR et al.: The impact of foodborne calicivirus disease: the Minnesota experience. J. Infect. Dis. (2000) 181(Suppl. 2):S281-S283.
55. XI JN, GRAHAM DY, WANG KN, ESTES MK: Norwalk virus genome cloning and characterization. Science (1990) 250:1580-1583.
56. BALL JM, GRAHAM DY, OPEKUN AR, GILGER MA, GUERRERO RA, ESTES MK: Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology (1999) 117:40-48.
57. TACKET CO, SZTEIN MB, LOSONSKY GA, WASSERMAN SS, ESTES MK: Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol. (2003) 108:241-247.
58. MASON HS, BALL JM, SHI JJ, JIANG X, ESTES MK, ARNTZEN CJ: Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. USA (1996) 93:5335-5340. Demonstration of the immunogenicity of transgenic plant vaccine against NV in mice.
59. TACKET CO, MASON HS, LOSONSKY G, ESTES MK, LEVINE MM, ARNTZEN CJ: Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. (2000) 182:302-305. Phase I study of transgenic potato vaccine expressing NVCP.
60. LAGOS R, KOTLOFF K, HOFFENBACH A et al.: Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr. Infect. Dis. J. (1998) 17:294-304.
61. YU J, LANGRIDGE WH: A plant-based multicomponent vaccine protects mice from enteric diseases. Nat. Biotechnol. (2001) 19:548-552.
62. DOUCE G, GIANNELLI V, PIZZA M et al.: Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect. Immun. (1999) 67:4400-4406.
63. STEIN KE, WEBBER KO: The regulation of biologic products derived from bioengineered plants. Curr. Opin. Biotechnol. (2001) 12:308-311.
64. STOKSTAD E, VOGEL G: Agrobiotechnology. Mixed message could prove costly for GM crops. Science (2003) 302:542-543.
65. RUF S, HERMANN M, BERGER IJ, CARRER H, BOCK R. Stable genetic transformation of tomato plastids and expression of a foreign protein in fruit. Nat. Biotechnol. (2001) 19:870-875.
66. STROBER W, KELSALL B, MARTH T: Oral tolerance. J. Clin. Immunol. (1998) 18:1-30.
67. HUSBY S, MESTECKY J, MOLDOVEANU Z, HOLLAND S, ELSON CO: Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J. Immunol. (1994) 152:4663-4670.
68. GONZALEZ C, HONE D, NORIEGA FR et al.: Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. (1994) 169:927-931.
69. SEPPALA U, ALENIUS H, TURJANMAA K, REUNALA T, PALOSUO T, KALKKINEN N: Identification of patatin as a novel allergen for children with positive skin prick test responses to raw potato. J. Allergy Clin. Immunol. (1999) 103:165-171.
70. THANAVALA Y, YANG YF, LYONS P, MASON HS, ARNTZEN C: Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc. Natl. Acad. Sci. USA (1995) 92:3358-3361.
71. MASON HS, LAM DM, ARNTZEN CJ: Expression of hepatitis B surface antigen in transgenic plants. Proc. Natl. Acad. Sci. USA (1992) 89:11745-11749.
72. GAO Y, MA Y, LI M et al. Oral immunization of animals with transgenic cherry tomatillo expressing HBsAg. World J. Gastroenterol. (2003) 9:996-1002.
73. SMITH ML, MASON HS, SHULER ML: Hepatitis B surface antigen (HBsAg) expression in plant cell culture: Kinetics of antigen accumulation in batch culture and its intracellular form. Biotechnol. Bioeng. (2002) 80:812-822.
74. KAPUSTA J, MODELSKA A, FIGLEROWICZ M et al.: A plant-derived edible vaccine against hepatitis B virus. FASEB J. (1999) 13:1796-1799.
75. KAPUSTA J, MODELSAK A, PNIEWSKI T et al.: Oral immunization of human with transgenic lettuce expressing hepatitis B surface antigen. Adv. Exp. Biol. Med. (2001) 495:299-303.
76. RICHTER LJ, THANAVALA Y, ARNTZEN CJ, MASON HS: Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat. Biotechnol. (2000) 18:1167-1171.
77. MA Y, LIN SQ, GAO Y et al: Expression of ORF2 partial gene of hepatitis E virus in tomatoes and immunoactivity of expression products. World J. Gastroenterol. (2003) 9:2211-2215.
78. MCGARVEY PB, HAMMOND J, DIENELT MM et al: Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology (NY) (1995) 13:1484-1487.
79. MODELSKA A, DIETZSCHOLD B, SLEYSH N et al.: Immunization against rabies with plant-derived antigen. Proc. Natl. Acad. Sci. USA (1998) 95:2481-2485.
80. YUSIBOV V, HOOPER DC, SPITSIN SV et al.: Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine (2002) 20:3155-3164.
81. TACKABERRY ES, PRIOR F, BELL M et al.: Increased yield of heterologous viral glycoprotein in the seeds of homozygous transgenic tobacco plants cultivated underground. Genome (2003) 46:521-526.
82. TACKABERRY ES, DUDANI AK, PRIOR F et al.: Development of biopharmaceuticals in plant expression systems: cloning, expression and immunological reactivity of human cytomegalovirus glycoprotein B (UL55) in seeds of transgenic tobacco. Vaccine (1999) 17:3020-3029.
83. KHANDELWAL A, SITA GL, SHAILA MS: Expression of hemagglutinin protein of rinderpest virus in transgenic tobacco and immunogenicity of plant-derived protein in a mouse model. Virology (2003) 308:207-215.
84. CASTANON S, MARIN MS, MARTIN-ALONSO JM et al.: Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus. J. Virol. (1999) 73:4452-4455.
85. DUS SANTOS MJ, WIGDOROVITZ A, TRONO K et al.: A novel methodology to develop a foot and mouth disease virus (FMDV) peptide-based vaccine in transgenic plants. Vaccine (2002) 20:1141-1147.
86. CARRILLO C, WIGDOROVITZ A, OLIVEROS JC et al.: Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants. J. Virol. (1998) 72:1688-1690.
87. CARRILLO C, WIGDOROVITZ A, TRONO K et al.: Induction of a virus-specific antibody response to foot and mouth disease virus using the structural protein VP1 expressed in transgenic potato plants. Viral Immunol. (2001) 14:49-57.
88. WIGDOROVITZ A, CARRILLO C, DUS SANTOS MJ et al.: Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology (1999) 255:347-353.
89. GOMEZ N, WIGDOROVITZ A, CASTANON S et al.: Oral immunogenicity of the plant derived spike protein from swine-transmissible gastroenteritis coronavirus. Arch. Virol. (2000) 145:1725-1732.
90. TUBOLY T, YU W, BAILEY A et al.: Immunogenicity of porcine transmissible gastroenteritis virus spike protein expressed in plants. Vaccine (2000) 18:2023-2028.
91. ZHANG GG, RODRIGUES L, ROVINSKI B, WHITE KA: Production of HIV-1 p24 protein in transgenic tobacco plants. Mol. Biotechnol. (2002) 20:131-136.
92. MARQUET-BLOUIN E, BOUCHE FB, STEINMETZ A, MULLER CP: Neutralizing immunogenicity of transgenic carrot (Daucus carota L.)-derived measles virus hemagglutinin. Plant Mol. Biol. (2003) 51:459-469.
93. WEBSTER DE, COONEY ML, HUANG Z et al.: Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine. J. Virol. (2002) 76:7910-7912.
94. WEBSTER DE, THOMAS MC, STRUGNELL RA, DRY IB, WESSELINGH SL: Appetising solutions: an edible vaccine for measles. Med. J. Aust. (2002) 176:434-437.
95. HUANG Z, DRY I, WEBSTER D, STRUGNELL R, WESSELINGH S: Plant-derived measles virus hemagglutinin protein induces neutralizing antibodies in mice. Vaccine (2001) 19:2163-2171.
96. BIEMELT S, SONNEWALD U, GALMBACHER P, WILLMITZER L, MULLER M: Production of human papillomavirus type 16 virus-like particles in transgenic plants. J. Virol. (2003) 77:9211-9220.
97. WARZECHA H, MASON HS, LANE C et al.: Oral immunogenicity of human papillomavirus-like particles expressed in potato. J. Virol. (2003) 77:8702-8711.
98. MATSUMURA T, ITCHODA N, TSUNEMITSU H: Production of immunogenic VP6 protein of bovine group A rotavirus in transgenic potato plants. Arch. Virol. (2002) 147:1263-1270.
99. GIL F, BRUN A, WIGDOROVITZ A et al.: High-yield expression of a viral peptide vaccine in transgenic plants. FEBS Lett. (2001) 488:13-17.
100. BELANGER H, FLEYSH N, COX S et al.: Human respiratory syncytial virus vaccine antigen produced in plants. FASEB J. (2000) 14:2323-2328.
101. SANDHU JS, KRASNYANSKI SF, DOMIER LL, KORBAN SS, OSADJAN MD, BUETOW DE: Oral immunization of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response. Transgenic Res. (2000) 9:127-135.
102. LAUTERSLAGER TG, FLORACK DE, VAN DER WAL TJ et al.: Oral immunisation of naive and primed animals with transgenic potato tubers expressing LT-B. Vaccine (2001) 19:2749-2755.
103. VIEIRA DA SILVA J, GARCIA AB, VIEIRA FLORES VM, SOUSA DE MACEDO Z, MEDINA-ACOSTA E: Phytosecretion of enteropathogenic Escherichia coli pilin subunit A in transgenic tobacco and its suitability for early life vaccinology. Vaccine (2002) 20:2091-2101.
104. DANIELL H, LEE SB, PANCHAL T, WIEBE PO: Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts. J. Mol. Biol. (2001) 311:1001-1009.
105. JANI D, MEENA LS, RIZWAN-UL-HAQ QM, SINGH Y, SHARMA AK, TYAGI AK: Expression of cholera toxin B subunit in transgenic tomato plants. Transgenic Res. (2002) 11:447-454.
106. RIGANO MM, ALVAREZ ML, PINKHASOV J et al.: Production of a fusion protein consisting of the enterotoxigenic Escherichia coli heat-labile toxin B subunit and a tuberculosis antigen in Arabidopsis thaliana. Plant Cell Rep. (2004) 22(7):502-508.
107. AZHAR AM, SINGH S, ANAND KP, BHATNAGAR R. Expression of protective antigen in transgenic plants: a step towards edible vaccine against anthrax. Biochem. Biophys. Res. Commun. (2002) 299:345-351.
108. LEE RW, STROMMER J, HODGINS D, SHEWEN PE, NIU Y, LO RY: Towards development of an edible vaccine against bovine pneumonic pasteurellosis using transgenic white clover expressing a Mannheimia haemolytica A1 leukotoxin 50 fusion protein. Infect. Immun. (2001) 69:5786-5793.